Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
psychopraxis. neuropraxis
Erschienen in: psychopraxis. neuropraxis 1/2017

01.02.2017 | Psychiatrie

Therapie depressiver Störungen mit selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI)

verfasst von: Dr. Wolfgang Novak, Andreas Erfurth

Erschienen in: psychopraxis. neuropraxis | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Antidepressiva sind eine inhomogene Gruppe von Substanzen, unter denen sich die selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI) als First-line-Medikamente bei Depressionen etabliert haben. Der Vorteil der SSRI gegenüber Antidepressiva der ersten Generation liegt in ihrem günstigeren Nebenwirkungsprofil, der hohen therapeutischen Breite und den niedrigeren Drop-out-Raten bei vergleichbarer Wirksamkeit. Escitalopram und Sertralin zeichnen sich möglicherweise durch Wirksamkeitsvorteile gegenüber den anderen SSRI aus.
Vorheriger Artikel Aggression und serotoninerge Dysfunktion
Nächster Artikel Welche Behandlungen sind für unsere Patienten zielführend?
Literatur
1.
Möller H‑J, Laux G, Kapfhammer H‑P (Hrsg) (2011) Psychiatrie, Psychosomatik, Psychotherapie, 4. Aufl. Springer, Berlin Heidelberg
2.
Jacobi F, Wittchen H‑U, Hölting C, Höfler M, Pfister H, Müller N, Lieb R (2004) Prevalence, co-morbiditiy and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey [GHS]. Psychol Med 34:1–15CrossRef
3.
Murray C, Lopez A (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349:1498–1504CrossRefPubMed
4.
Kasper S, Lehofer M, Doering S, Geretsegger C, Frey R, Haring C et al (2012) Depression – Medikamentöse Therapie. Clin Neuropsy (Sonderausgabe Nov 2012):3–23
5.
6.
aan het Rot M, Mathew SJ, Charney DS (2009) Neurobiological mechanisms in major depressive disorder. CMAJ 180(3):305–313CrossRef
7.
Linden M, Müller WE (2005) Rehabilitations-Psychopharmakotherapie: Arzneimittelbehandlung chronifizierender und chronifizierter psychischer Syndrome, 1. Aufl. Deutscher Ärzte-Verlag, Köln
8.
Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1119–1127CrossRef
9.
Rothenhäusler H‑B, Täschner K‑L (2007) Kompendium Praktische Psychiatrie. Springer, Wien NewYork
10.
Müller H‑J, Laux G, Deister A (2009) Psychiatrie und Psychotherapie, 4. Aufl. Duale Reihe. Thieme, Stuttgart
11.
Benkert O, Hippius H (2013) Kompendium der Psychiatrischen Pharmakotherapie, 9. Aufl. Springer, Berlin HeidelbergCrossRef
12.
Lüllmann H, Mohr K, Hein L (2006) Pharmakologie und Toxikologie: Arzneimittelwirkungen verstehen – Medikamente gezielt einsetzen, 16. Aufl. Thieme, Stuttgart
13.
Beubler E (2011) Kompendium der Pharmakologie. Gebräuchliche Arzneimittel in der Praxis, 3. Aufl. Springer, WienCrossRef
14.
Riederer P, Laux G, Pöldinger W (Hrsg) (2002) Neuro-Psychopharmaka, 2. Aufl. Bd. 3. Springer, Wien
15.
DeVane CL (1999) Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 19(4):443–466CrossRefPubMed
16.
Kriegebaum C, Gutknecht L, Schmidt A, Lesch K‑P, Reif A (2010) Serotonin Kompakt – Teil 1: Neurobiologische und entwicklungsgenetische Grundlagen. Fortschr Neurol Psychiat 78:319–331CrossRefPubMed
17.
Erfurth A, Gardier AM, Ribeiro E, Wurtman RJRJ (1994) Effects of subchronic pretreatment with D‑fenfluramine or p‑chloroamphetamine on [3 H]inositolmonophosphate accumulation in rat cortical miniprisms. Brain Res 665(1):107–114CrossRefPubMed
18.
Gardier AM, Kaakkola S, Erfurth A, Wurtman RJ (1992) Effects of methiothepin on changes in brain serotonin release induced by repeated administration of high doses of anorectic serotoninergic drugs. Brain Res 588(1):67–74CrossRefPubMed
19.
Kroeze Y, Zhou H, Homberg JR (2012) The genetics of selective serotonin reuptake inhibitors. Pharmacol Ther 136:375–400CrossRefPubMed
20.
Mascio MD, Giovanni GD, Matteo VD, Prisco S, Esposito E (1998) Selective serotonin reuptake inhibitors reduce the spontaneus activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 46(6):547–554CrossRefPubMed
21.
Dremencov E, Mansari ME, Blier P (2009) Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci 34(3):223–229PubMedPubMedCentral
22.
Dremencov E, Mansari ME, Blier P (2007) Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 61:671–678CrossRefPubMed
23.
Castanon N, Leonard BE, Neveu PJ, Yirmiya R (2002) Effects of antidepressants on cytokine production and action. Brain Behav Immun 16:569–574CrossRefPubMed
24.
Tao R, Calley CS, Hart J, Mayes TL, Nakonezny PA, Lu H et al (2012) Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry 169(4):381–388CrossRefPubMedPubMedCentral
25.
Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr. (1992) The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 572(1–2):117–125CrossRefPubMed
26.
Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010) Antidepressant drug effects and depression severity – a patient-level Meta-analysis. JAMA 303(1):47–53CrossRefPubMedPubMedCentral
27.
Melander H, Salmonsen T, Abadie E, v. Zwieten-Boot B (2008) A regulatory apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623–627CrossRefPubMed
28.
Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143(6):415–426CrossRefPubMed
29.
Kennedy SH, Anderson HF, Lam RW (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Rev Psychiatr Neurosci 31(2):122–131
30.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgnis J, Churchill R et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758CrossRefPubMed
31.
Barbui C, Hotopf M (2001) Amitriptyline versus the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br J Psychiatry 178:129–144CrossRefPubMed
32.
Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19–36CrossRefPubMed
33.
Spielmans GI, Berman MI, Usitalo AN (2011) Psychotherapy versus second-generation antidepressants in the treatment of depression. J Nerv Ment Dis 199(3):142–149CrossRefPubMed
34.
Dreimüller N, Tadic A, Dragicevic A, Boland K, Bondy B, Lieb K et al (2012) The serotonin transporter promoter polymorphism [5-HTTLPR] affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry 45:108–113CrossRefPubMed
35.
Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M (2009) SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiartr Genet Dec 19(6):281–291CrossRef
36.
Young EA (2009) Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res 43(5):503–511CrossRefPubMed
37.
Lee K‑U, Lee YM, Nam J‑M, Lee H‑K, Kweon Y‑S, Lee CT, Jun T‑Y (2010) Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investig 7:55–59CrossRefPubMedPubMedCentral
38.
Trindade E, Menon D, Topfer L‑A, Coloma C (1998) Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 159(10):1145–1252
39.
Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, Beyenburg S (2004) „Dopamine-dependent“ side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry August 65(8):1064–1068CrossRef
40.
41.
Barbui C, Esposito E, Cipriani A (2009) Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 180(3):291–297CrossRefPubMedPubMedCentral
42.
Leon AC, Salomon DA, Li C, Diedorowicz JG, Coryell WH, Endicott J, Keller MB (2011) Antidepressants and risk of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry 72(5):580–586CrossRefPubMedPubMedCentral
43.
Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH (2003) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding – a population-based cohort study. Arch Intern Med 163:59–64CrossRefPubMed
44.
Hackam DG, Mrkobrada M (2012) Selective serotonin reuptake inhibitors and brain hemorrhage. Neurology 79:1862–1865CrossRefPubMed
45.
Barbey JT, Roose SP (1998) SSRI safety in overdose. J Clin Psychiatry 59(15):42–48PubMed
46.
Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS et al (2012) Antidepressant response in patients with major depressive disorder exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 169:1065–1072CrossRefPubMedPubMedCentral
47.
Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M et al (2007) World Federation of Societies of Biological Psychiatry [WFSBP] guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8(2):67–104CrossRefPubMed
48.
Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003) Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64(4):413–420CrossRefPubMed
49.
Posternak M, Baer L, Nierenberg AA, Fava M (2011) Response rates to fluoxetine in subjects who initially show no improvement. J Clin Psychiatry 72(7):949–954CrossRefPubMed
50.
Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al (2006) Bupropion-SR, Sertralin, or Venlafaxin-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242CrossRefPubMed
51.
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661CrossRefPubMed
52.
Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR Jr., Vazquez DM (2005) Selective Serotonin Reuptake Inhibitor [SSRI] use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 25:595–604CrossRefPubMed
53.
Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ (2012) Who benefits from antidepressants? Synthesis of 6‑week patient-level outcomes from double-blind placebo controlled randomized trials of Fluoxetine and Venlafaxine. Arch Gen Psychiatry 69(6):572–557PubMedPubMedCentral
54.
Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH (2016) Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 173(2):174–183CrossRefPubMed
55.
Eke AC, Saccone G, Berghella V (2016) Selective serotonin reuptake inhibitor [SSRI] use during pregnancy and risk of preterm birth: a systematic review and meta-analysis. BJOG 123(12):1900–1907CrossRefPubMed
56.
Alwan S, Friedman JM, Chambers C (2016) Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. CNS Drugs 30:499–515CrossRefPubMed
57.
Viuff AC, Pedersen LH, Kyng K, Staunstrup NH, Børglum A, Henriksen TB (2016) Antidepressant medication during pregnancy and epigenetic changes in umbilical cord blood: a systematic review. Clin Epigenetics 8(1):94CrossRefPubMedPubMedCentral
58.
Kremer M, Salvat E, Muller A, Yalcin I, Barrot M (2016) Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience 338:183–206CrossRefPubMed
59.
60.
Sachs G, Erfurth A (2015) Kognition bei depressiven Störungen. Psychoprax Neuroprax 18:172–179CrossRef
61.
Metadaten
Titel
Therapie depressiver Störungen mit selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI)
verfasst von
Dr. Wolfgang Novak
Andreas Erfurth
Publikationsdatum
01.02.2017
Verlag
Springer Vienna
Erschienen in
psychopraxis. neuropraxis / Ausgabe 1/2017
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI
https://doi.org/10.1007/s00739-016-0371-5

Weitere Artikel der Ausgabe 1/2017

psychopraxis. neuropraxis 1/2017 Zur Ausgabe

Psychiatrie

Aggression und serotoninerge Dysfunktion

Neurologie

Inzidentelle Befunde vaskulärer Ätiologie in der kranialen MRT

Brief des Herausgebers

Agitation und Aggression

aktuell

aktuell

Leserbrief

Wie sieht die Versorgungsrealität in Österreich für Patienten mit komplexem Behandlungs- und Betreuungsbedarf aus?

Neurologie

Amyloid-PET und Alzheimer-Diagnose